Arellano Esperanza Arriola, Díaz Verónica Díaz, Rodríguez Joaquín José Cabrera
Department Medical Oncology, Universitary Hospital Puerta del Mar, Cádiz, Spain.
Department of Radiation Oncology, Universitary Hospital Puerta del Mar, Cádiz, Spain.
J Clin Transl Res. 2020 Oct 29;6(4):109-120.
Patients with unresectable stage III non-small-cell lung cancer constitute a heterogeneous group in which the available treatments may range from radical therapies with radio-chemotherapy to supportive treatments depending on the extent of the disease and comorbidities present. For years the standard treatment based on the combination of chemotherapy and radiotherapy (RT) has remained unchanged and survival outcomes have been poor.
Recent advances in molecular biology and RT technology have resulted in improved survival. This article reviews the treatments that constitute current standard treatment in unresectable advanced lung cancer and the situations and indications for the management of patients who are not candidates for radical therapy.
Although unresectable lung cancer does not have a good prognosis, new drugs and new technologies in radiation oncology can offer treatment options adapted to the patient's clinical situation, ranging from therapies administered with radical intent to others aimed mainly at improving the patient's quality of life, which, judiciously chosen, will provide optimal management of the patient.
不可切除的III期非小细胞肺癌患者构成了一个异质性群体，根据疾病程度和并存疾病情况，可用治疗方法范围从放化疗的根治性治疗到支持性治疗。多年来，基于化疗和放疗（RT）联合的标准治疗一直未变，生存结果较差。
分子生物学和放疗技术的最新进展已使生存率有所提高。本文综述了构成不可切除晚期肺癌当前标准治疗的治疗方法，以及不适合根治性治疗患者的管理情况和适应证。
尽管不可切除肺癌预后不佳，但放射肿瘤学中的新药和新技术可为适应患者临床情况的治疗选择提供支持，从根治性治疗到主要旨在改善患者生活质量的其他治疗方法，经过明智选择，将为患者提供最佳管理。
